The natural history of branch ductYtype intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas remains unclear. We conducted a retrospective long-term follow-up study for malignant transformation (MT) of BD-IPMNs focusing on morphological changes.
I
ntraductal papillary mucinous neoplasms (IPMNs) are a unique entity of pancreatic tumor defined as an intraductal mucinproducing neoplasm with a tall columnar mucin-containing epithelium with or without papillary projections, which shows a wide spectrum of histological differentiation from hyperplasia to invasive carcinoma. Intraductal papillary mucinous neoplasm has been the subject of many studies since the first report by Ohashi et al 1 in 1982 and has been well characterized. 2Y5 In 2004, the 11th Congress of the International Association of Pancreatology was held in Sendai, Japan, for the establishment of consensus guidelines. In 2006, guidelines for the management of IPMN/MCN were published; however, many issues remain unresolved, including how to diagnose the disease type, the definition of mural nodules, the indications for surgery, and the follow-up procedure (the modality that should be adopted and the length of follow-up interval that is appropriate). 6 Surveying the natural history of IPMNs (eg, when and how they cause malignant alterations in both IPMN itself and coexistent invasive ductal cancer [IDC] ) is essential for determining the timing of surgical intervention. There have been several studies on the natural history of branch ductYtype IPMNs (BD-IPMNs), but only a few detailed studies on this theme have been based on morphological changes. 7Y16 In daily clinical settings, a practical and reliable diagnostic modality needs to be identified, even if, which is only for the qualified expert. Several studies have reported the usefulness of fluid analysis and cytology using specimens collected by transpapillary or endoscopic ultrasonographyYguided fine needle aspiration (EUS-FNA), but the prediction of malignancy is still difficult. 17Y21 Therefore, at present, surgical indications are determined on the basis of morphological changes of IPMNs.
On the other hand, recent advances in diagnostic imaging techniques have allowed detailed imaging diagnosis. Electronic radial EUS is a modality that has high spatial and contrast resolution, allowing detailed evaluation of the main tumor, that is, the mural nodule and changes in the dilated branches and communication with main pancreatic duct (MPD) system, as well as screening for other lesions in the pancreas. 22Y24 We have reported the usefulness of the morphological classification of mural nodules by using contrast-enhanced EUS (CE-EUS).
biological behavior remain unclear. Tanno et al reported the natural history of BD-IPMNs without mural nodules. However, there is no clear consensus on the management of these micronodules. Therefore, to clarify the natural history of BD-IPMNs, we performed a retrospective study on the association between malignant transformation (MT) and morphological changes in patients with BD-IPMNs for whom long-term follow-up was performed mainly by CE-EUS.
MATERIALS AND METHODS

Patients
This study was approved by the Institutional Review Board of Nagoya University Graduate School of Medicine. Clinical records, EUS images, radiological data, pathology, and surgical reports in this study were reviewed retrospectively. There were 225 patients who had undergone CE-EUS as their first examination for BD-IPMNs between January 2001 and October 2009. Of these, 142 patients had been observed for more than 12 months, and 78 patients underwent surgical resection after the initial diagnosis. These 142 patients were included in this study. Inclusion criteria for this study were asymptomatic BDIPMNs without any dilatation of the MPD and obvious mural nodules. We excluded the cases with malignancy-related findings as follows: mural nodules greater than 5 mm (by CE-EUS), morphological types of mural nodule III/IV (by CE-EUS), 25 MPD greater than 6 mm, and malignant cells in the pancreatic juice (by ERP). In accordance with the international consensus guidelines, we classified patients into 2 groups at the initial diagnosis: low-risk group including the cases of BD-IPMN without high-risk stigmata: cyst 29 mm or less, MPD 5 mm or less, and mural nodules 4 mm or less (by CE-EUS), and high risk group, which included cases with any deviation from the above image findings. The clinical courses of all BD-IPMNs are shown in Figure 1 . As for the follow-up cases, the clinical diagnosis of IPMN was based on the presence of mucus identified on ERP or the presence of communication between the cystic lesion and MPD on at least 1 modality.
The MT of IPMN itself was defined as proof of malignant IPMN (IPMC and invasive IPMN) in surgical specimens or cytological specimens in ERP. Coexistent IDC was defined as development of invasive ductal carcinoma distant from the IPMN lesion. Unresectable cases were diagnosed by both positive EUS-FNA results and image findings.
The MT of IPMN itself during the follow-up period was evaluated by the Kaplan-Meier method, and the factors contributing to the MT of IPMN itself were analyzed by employing Cox proportional hazard model. 9, 10 To evaluate factors that are useful for predicting malignant IPMNs in patients who have undergone a resection, 16 clinicopathological and imaging parameters were classified into nominal and continuous variables and evaluated by univariate analysis. 25 Nominal variables included sex, symptoms (+ or j), diabetes mellitus (+ or j), number of cysts (single or multiple lesions), EUS mural nodule type 3 or 4 (+ or j), 25 computed tomography (CT) mural nodule (+ or j), the status at initial diagnosis (low-risk group/highrisk group), enlargement of cyst (+ or j), enlargement of MPD (+ or j), enlargement of mural nodules (+ or j), and MPD involvement (+ or j). Continuous variables included age, size of cyst, size of MPD, size of mural nodules (measured at operation), and the nodule growth rate (past year/total followup term).
Pathological diagnosis was based on the World Health Organization criteria (third edition), the international guidelines for the management of IPMN, and the Japan Pancreas Society's Classification of Pancreatic Carcinoma. Adenoma (IPMA) was classified as benign, and for comparison, carcinoma in situ (IPMC), invasive carcinoma derived from IPMN (invasive IPMN), and the occurrence of IDC (coexistent IDC) were classified as malignant.
26Y28
Definitions
The surgical indications for IPMN in our institute were main ductYtype IPMN (MD-IPMN), BD-IPMN with a mural nodule, symptomatic IPMN, and coexistent IDC. The follow-up criteria were the patient's refusal to undergo surgery and IPMN without mural nodules on CE-EUS. These BD-IPMNs were followed up by CE-EUS or by CT every 6 months. Patients showing neither mural nodules nor morphological changes for 1 year or more were examined by ultrasound (US), CE-EUS, CT, or MRI annually. During observation, surgery was recommended for patients who presented at least one of the following features: occurrence of remarkable symptoms (eg, pancreatitis, jaundice, abdominal or back pain that required medication) and/or enlargement or occurrence of mural nodules, change of morphological type of mural nodules by CE-EUS (type III/IV), 25 enlargement of MPD, and development of MPD involvement with intraductal tumors.
The type of IPMN was determined mainly by CE-EUS and also by at least one of CT, US, ERCP, and intraductal ultraonography. The MD-IPMN was defined as IPMNs with grossly involving MPD with dilatation of MPD 10 mm or greater or IPMNs with mural nodules detected by CE-EUS mainly in the dilated MPD. The BD-IPMN was defined as an IPMN with a dilated branch with or without mural nodules on the cystic wall. The cases in which mural nodules had developed along the epithelium of the MPD for more than 10 mm were defined as ''MPD involvement.''
The maximum sizes of cyst and MPD were measured by CE-EUS or MD-CT. Location of cyst was divided according to anatomic pancreatic portion in pancreas head, body, and tail. Multiple cysts were defined as cases with distribution for 2 or more pancreatic portions.
A mural nodule was defined as an EUS-detectable protruding component in the cystic cavity or MPD, with a blood flow signal confirmed by CE-EUS, excluding mucous clots. We reported the correlation between CE-EUSYdetected mural nodules and pathological findings. Mural nodules were classified into 4 types: type I (low papillary nodule) was defined as low, fine, protruding components in the cyst wall or MPD epithelium; type II (polypoid nodule), as a smooth-surfaced component protruding into the cyst or MPD; type III (papillary nodule), as a protruding component with a thickened cyst wall or MPD epithelium or with an irregular, villous structure; and type IV (invasive nodule), as a lesion in which papillary nodules were connected to a hypoechoic area ill-defined from the pancreatic parenchyma. 25 If more than 1 type of nodule was present in a lesion, the nodular component composing the main lesion was compared with the pathological tissue. Intraductal papillary mucinous neoplasm with type III or IV nodules was highly suspected of being malignant IPMN; in contrast, type I ''low papillary nodule'' had a lower risk of malignancy. We defined ''type I nodules'' as micronodules in this study. Mural nodules on CT images were defined as enhanced protruding components along the cystic wall or a dilated MPD found using a multidetector row CT (MD-CT; slice thickness was set at 2 mm). In accordance with these diagnostic criteria, we defined mural nodules greater than 5 mm (by CE-EUS or MD-CT) and CE-EUS nodule type III/IV as obvious mural nodules in this study.
CE-EUS Technique
After providing written informed consent, the patients received conscious sedation with intravenous diazepam under appropriate cardiorespiratory monitoring. Contrast-enhanced EUS of the main lesion (the site of a mural nodule) was performed using 2.5 g of the contrast medium Levovist (Nihon Schering Co, Ltd, Tokyo, Japan) or 16 KL of Sonazoid (Daiichi-Sankyo, Tokyo, Japan; GE Healthcare, Milwaukee, Wis) to investigate the hemodynamics of the mural nodule. Levovist is made of galactose microbubbles (air microbubbles) and a small (0.1%) admixture of palmitic acid, and Sonazoid is made of perflubutane microbubbles. After its injection into the peripheral vein, it temporarily enhances US echoes. It is widely used in some fields. 29Y31 The apparatuses used were GF-UE260 (OLYMPUS, Tokyo, Japan), EG-3630UR, and EG-3670URK (PENTAX, Tokyo, Japan) (electronic radial) as endoscopes and Prosound >-10 (ALOKA, Tokyo, Japan), EUB-8500, and HV-900 (Hitachi, Tokyo, Japan) as US diagnostic machines.
Image Analysis
Contrast-enhanced EUS images were recorded on digital videotape. Three expert endoscopists (Y.H., A.I., and E.O.) in our hospital evaluated these image findings.
Concerning the morphological changes in IPMN, changes in the diameters of the cyst, MPD, and mural nodules and their diameters at initial and final diagnoses were evaluated. In the follow-up period, enlargements of the cyst, MPD, and mural nodule were defined as progressions of more than 10, 3, and 3 mm in maximum diameter, respectively.
In patients who underwent resection during the followup period, mural nodules were morphologically classified by CE-EUS, and the nodule growth rate (past year/total follow-up term) was calculated; these were then compared with histopathological findings. The nodule growth rate was calculated as follows: (h 1 j h 2 ) / t (h 1 = latest height of mural nodule on CE-EUS, h 2 = previous height of mural nodule on CE-EUS, t = duration of follow-up).
Statistical Analysis
Statistical calculations were performed using SPSS Statistics 17.0 for Windows. W 2 and Fisher exact tests were used to detect the association between malignancy and categorical parameters. Continuous parameters are presented as mean T SD and/or median (range). Student t test was used for continuous parameters. Analysis for MT of IPMN itself was performed using the Kaplan-Meier method. Hazard ratios (HRs) of predictive variables for MT were calculated with univariate and multivariate Cox proportional-hazard models to adjust for multiple potential confounders. P G 0.05 was considered statistically significant.
RESULTS
Changes in IPMN Image Findings During the Follow-Up Period
The clinical findings of the patients are summarized in Table 1 . Follow-up observation was performed for 142 patients for a median period of 42.5 months (range, 12Y105 months). The mean number of CE-EUS procedures was 2.50 T 1.90 (range, 1Y13). Concerning changes in image findings, enlargements of the cysts, MPD, and mural nodules were seen in 32 (22.4%), 19 (13.3%), and 35 (24.4%) cases, respectively. The occurrence of mural nodules was found in 20 patients (14.0%). Mural nodules including micronodules were not detected in 81 cases (56.6%) at the initial diagnosis by CE-EUS. Finally, the mean sizes of cysts, MPD, and mural nodules were 24.4 T 11.6, 3.0 T 1.7, and 3.7 T 4.8 mm, respectively (Table 2) . Main pancreatic duct involvement was seen in 19 cases (13.3%) at operation. In 9 of 19 cases, mural nodules had developed to MPD epithelium in the follow-up period. Development of symptoms was seen in 17 patients in the follow-up period. Acute pancreatitis occurred in 7 patients. The symptoms in the follow-up period included 12 abdominal pain cases (70.6%), 3 jaundice cases (17.6%), 7 abdominal discomfort cases (41.1%), and 8 back pain cases (47.1%). There were 10 patients with symptoms who did not undergo surgery; 3 of these 10 cases were unresectable. Symptoms of the other 7 patients were mild and transient abdominal pain, mild back pain, and obstructive jaundice caused by choledocholithiasis. These 7 cases had no morphological change of IPMNs in image findings and they are under follow-up.
Identification of Predictors of Malignant Transformation of IPMN
Malignant transformation of IPMN itself developed in 9 patients (6.3%). The 5-year MT rate as analyzed by the KaplanMeier method was 10.7% (95% confidence interval [CI], 2.5%Y18.9%; Fig. 2A ), and the incidence was 2.1% per year. In contrast, coexistent IDC distant from the IPMN site occurred in 5 patients (3.5%) during the follow-up period. The diagnoses were confirmed by pathological findings in 2 patients. Three unresectable cases were diagnosed from the both positive EUS-FNA results and image findings.
The predictive factors of MT of IPMN itself by Cox proportional hazard model are summarized in Table 3 . Multivariate analysis showed that MPD involvement (HR, 6.19; 95% CI, 1.0Y65.2; P = 0.0399) and existence of mural nodules at initial diagnosis (HR, 7.42; 95% CI, 1.3Y80.3; P = 0.0261) were statistically significant. On the other hand, enlargement of cyst and MPD and development of symptoms were significant predictors only by univariate analysis. 
Comparison of the Changes in the Characteristics of Resected IPMN During Follow-Up With Pathological Diagnosis
Thirty patients (15 males) underwent surgery owing to morphological changes in BD-IPMNs during the follow-up period. The mean age at the time of operation was 68.4 T 9.3 years (range, 36Y82 years). The number of patients with symptoms was 7 (23.3%). Because morphological changes in IPMN, enlargements of cysts, MPD, and mural nodules were seen in 12 (40%), 8 (26.7%), and 25 (83.3%) cases, respectively, and the occurrence of a mural nodule was seen in 14 (46.7%). Main pancreatic duct involvement was seen in 12 (40%) (91 change was present in some patients) ( Table 4 ). The histopathological diagnosis of resected specimens is shown in Table 5 . No invasive IPMN was observed in patients who underwent resection at the time of the occurrence of new mural nodules (EUS MN[j] ).
Concerning the relationship between the location of mural nodules (namely, with or without MPD involvement) and pathological diagnosis in operative cases, half of cases (6 cases) with MPD involvement were malignant, and there was no significant relationship (P = 0.2159). In addition, for comparison of MPD involvement (+) or (j) and MPD size at the initial diagnosis in operated cases, there was no significant difference between these 2 groups (3.08 T 1.6 vs 2.97 T 1.1 mm, P = 0.8253).
Identification of Predictors of Malignant IPMNs in Surgical Cases
Univariate analysis of clinicopathological variables for the identification of predictors of malignancy showed that development of symptoms (P = 0.0293; odds ratio [OR], 7.08; 95% CI, 1.08Y46.7), MPD enlargement (P = 0.0256; OR, 6.40; 95% CI, 1.18Y35.4), MPD size (P = 0.0327), nodule size (P = 0.0097), and nodule growth rate (past year) (P = 0.0068) were significant predictors (Tables 6 and 7) .
DISCUSSION
Many issues remain unresolved concerning the management of IPMN. One is a method for the differentiation between malignant and benign tumors because IPMN exhibits various pathological features, ranging from adenoma to invasive carcinoma. Another issue concerns the types of IPMN that are susceptible to MT and how frequently they occur. As IPMN tends to occur in the elderly, its surgical indications and associated follow-up methods should be determined on the basis of its natural history, including the risk of coexistent IDC, in addition to the malignant potential of the tumor at the time of diagnosis. Ingkakul et al, 8 Tada et al, 9 and Uehara et al 10 reported 7Y21 A description of both clinicopathological and imaging features that can predict malignant alteration would be very useful for practical clinical settings. In daily clinical settings, a practical and reliable diagnostic modality needs to be identified, even if, which is only for the qualified expert.
The result of the analysis of MT of BD-IPMN reveals 2 important points. The first point is that BD-IPMNs with MPD involvement had greater malignant risk than BD-IPMNs without mural nodules or without MPD involvement. The second point is that EUS is a very useful modality to search for morphological changes of BD-IPMNs, such as serial changes of size and location of mural nodules and MPD. Several studies have shown that the diameter of the MPD or nodule at the time of diagnosis is a predictor of malignant IPMN. 32 In addition, serial morphological changes may be an important factor in follow-up cases.
The MT of IPMN itself was observed in 9 patients (6.3%). Malignant transformation of IPMN itself was considered to be present when the pathological examination of resected tissue or cytological specimens showed malignancy in patients in whom histological examination at the time of the initial diagnosis revealed no malignancy. None of the 109 patients who are currently being followed up have shown mural nodules with a diameter of 5 mm or greater or CE-EUS type 3 or 4 mural nodules, which would indicate malignancy, or malignancy based on the cytology of ERCP. Malignant transformation during follow-up was observed in 2 (2.0%) of 99 patients within lowrisk group. Furthermore, there was no case of MT among the patients without mural nodules including micronodules detected by CE-EUS at the initial diagnosis.
Evaluation of the 30 patients who underwent resection due to changes in their images and findings during the follow-up period showed no invasive IPMN in those without mural nodules at the initial diagnosis. Therefore, if resection is performed when CE-EUS reveals a new mural nodule during the follow-up period, it is possible for resections to be performed for carcinoma and the MPD enlargement to be significant factors. On the international consensus guideline, resection is recommended for BD-IPMN with cyst size greater than 30 mm. In our result, ''enlargement of cyst'' is the significant predictor for malignancy, but not size. On the other hand, concerning mural nodules, the nodular size at the time of resection and its growth rate over the year before surgery were significant predictors. Magnetic resonance cholangiopancreatography using secretin or MD-CT has been reported to be useful for observing the course of IPMN.
33Y35
However, mural nodules were identified by CT in only 56.7% (17/30) of patients who underwent resection, and identification was only possible using CE-EUS in approximately 40%. In 3 (27.3%) of the 11 patients with malignant IPMN treated by resection, only CE-EUS revealed mural nodules. We reported that IPMNs with type 1 mural nodule (ie, micronodules) had lower risk for malignancy in surgical series. However, the result of current study suggested that IPMNs had the potential risk for MT even the cases with micronodules. Although CE-EUS is considered to be more invasive and operator-dependent than CT or MRCP, it is essential for the evaluation of morphological changes in patients with mural nodules. Some studies have reported the usefulness of fluid analysis by EUS-FNA; however, its indications are still controversial owing to the risk of dissemination, and we have not used this technique at our institute.
36Y40
Further evaluations of the correlation between nodules detected by CE-EUS and MD-CT/ MRCP and EUS-FNA cytologic findings are needed in a future prospective study.
In conclusion, the MT of BD-IPMN itself including the development of coexistent IDC is not rare, and periodic followup observation is necessary for BD-IPMNs. In particular, it is strongly recommended that careful attention be paid to BDIPMNs with micronodules.
